GDLSK

filing

USTR SOLICITING COMMENTS ON THE REMOVAL OF CHINA SEC. 301 DUTIES FROM ADDITIONAL MEDICAL-CARE PRODUCTS

In a March 23, 2020 notice, the Office of the United States Trade Representative (“USTR”) has solicited comments identifying additional medical-care items that should be excluded from China Section 301 tariffs in light of the ongoing COVID-19 outbreak. The comment period will remain open at least until June 25, 2020 (subject to potential extensions as […]

UPDATE: USTR ANNOUNCES ADDITIONAL EXCLUSIONS GRANTED TO SEC. 301 LIST 3 PRODUCTS AND TECHNICAL AMENDMENTS TO PREVIOUS EXCLUSIONS

On February 19, 2020, the U.S. Trade Representative (“USTR”) announced that 47 additional HTS provisions and product descriptions will be excluded from the Section 301 trade remedies imposed on Chinese-origin products. The newly announced exclusions all relate to items on China 301 List 3 (the $200 billion trade action) which, unless excluded, are subject to […]